- Home
- ALPS vs HURA Comparison
ALPS vs HURA Comparison
Compare ALPS & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ALPS | HURA |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | Malaysia | United States |
| Employees | N/A | 22 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.4M | 144.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ALPS | HURA |
|---|---|---|
| Price | $0.68 | $2.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 24.0K | ★ 516.7K |
| Earning Date | 07-24-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $0.41 |
| 52 Week High | $1.72 | $3.90 |
Technical Indicators
Market Signals| Indicator | ALPS | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 36.69 | 44.28 |
| Support Level | $0.64 | $2.15 |
| Resistance Level | $1.11 | $2.20 |
| Average True Range (ATR) | 0.06 | 0.19 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 22.32 | 16.44 |
Price Performance
Historical ComparisonAbout ALPS ALPS Group Inc Ordinary Share
ALPS Group Inc is a fully integrated platform encompassing biotechnology research, medical, and wellness services specializing in predictive, precision and preventive health management. It aims to provide its clientele with access to DNA and mRNA sequencing, cellular therapy, as well as wellness and anti-aging products and services.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.